August 2026's Leading Growth Companies With Insider Confidence
The article highlights top growth companies in the United States with high insider ownership, indicating strong internal confidence. It details companies like Webull, Evolus, and Victoria's Secret, providing an overview of their operations, growth forecasts, and recent developments. The piece suggests that high insider ownership, coupled with robust earnings growth, makes these companies attractive investment prospects.
Renaissance Technologies LLC Lowers Stake in Evolus, Inc. $EOLS
Renaissance Technologies LLC significantly reduced its stake in Evolus, Inc. (NASDAQ:EOLS) by 57.6% in the first quarter, selling 460,875 shares and retaining 339,025 shares valued at $1.39 million. Despite this, institutional investors collectively own about 90.69% of Evolus, and several other funds have recently increased or initiated positions. Analysts maintain a "Moderate Buy" consensus rating for Evolus with an average price target of $14.50, significantly higher than its recent share price of $8.12.
Assenagon Asset Management S.A. Grows Stock Holdings in Evolus, Inc. $EOLS
Assenagon Asset Management S.A. significantly increased its stake in Evolus, Inc. (NASDAQ:EOLS) by 51.8% in the second quarter, now holding 908,180 shares valued at approximately $6.3 million. This move is part of a trend among institutional investors, who collectively own 90.69% of Evolus stock. The company maintains a "Moderate Buy" consensus rating from analysts, with shares trading above their 50-day and 200-day moving averages.
Trading Systems Reacting to (EOLS) Volatility
This article analyzes Evolus Inc. (NASDAQ: EOLS) using AI models to generate trading strategies. It highlights strong near and mid-term sentiment but a weak long-term outlook, identifying compelling upside potential as no resistance levels remain above the current price. The analysis provides specific entry, target, and stop-loss points for position, momentum breakout, and risk hedging strategies, alongside multi-timeframe signal analysis.
Evolus Inc (EOLS) Stock News Today
This page provides an overview of Evolus Inc (EOLS) stock news, earnings, analyst ratings, and key developments. It notes the current stock price, market cap, and indicates that more news will be coming soon. The page serves as a hub for investors to track information related to EOLS.
Evolus (NASDAQ:EOLS) Rating Increased to Buy at Wall Street Zen
Wall Street Zen has upgraded Evolus (NASDAQ:EOLS) from a "hold" to a "buy" rating, contributing to a "Moderate Buy" consensus among analysts with an average price target of $14.50. Shares of Evolus opened at $7.59, a 2.4% increase, and are nearing their 12-month high. Institutional ownership of Evolus is substantial at 90.69%, indicating strong investor confidence.
Evolus, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:EOLS) 2026-08-06
This article announces that Evolus, Inc. (EOLS) published its Q2 2026 earnings call presentation on August 6, 2026. The company reported Q2 EPS of -$0.02, beating estimates by $0.02, and revenue of $84.08 million, a 21.18% year-over-year increase, beating estimates by $2.54 million. The content highlights the availability of the slide deck from their earnings call.
Evolus Inc. Earnings Call Signals Confident Growth
Evolus, Inc. reported strong Q2 earnings with double-digit revenue growth and a third consecutive quarter of positive adjusted EBITDA, driven by its toxin franchise and growing international presence. Despite increased operating expenses and tariff uncertainty, the company raised its 2026 revenue guidance and reaffirmed long-term targets, signaling a confident outlook for profitable expansion. The company emphasized portfolio diversification and strategic investments, including a new skin quality licensing deal, as key drivers for future growth.
Evolus Inc (EOLS) News, Articles, Events & Latest Updates
This article provides a compilation of recent news, articles, and updates concerning Evolus Inc (EOLS). Key highlights include Evolus reporting strong Q2 2026 financial results with positive adjusted EBITDA, expanding partnerships, and announcing future earnings report dates. The company also reported inducement grants of restricted stock units and a significant partnership with IBSA to develop and commercialize Profhilo in the US.
Evolus, Inc. (EOLS) Reports Break-Even Earnings for Q2
Evolus, Inc. (EOLS) reported break-even earnings per share for Q2, outperforming the Zacks Consensus Estimate of a $0.01 loss and significantly improving from a $0.24 loss a year ago. The company also surpassed revenue estimates, posting $84.08 million for the quarter. Despite current market underperformance, its Zacks Rank #3 (Hold) suggests it will perform in line with the market.
Evolus, Inc. Q2 2026: Revenue $84.08M, EPS ($0.12) — 10-Q Summary
Evolus, Inc. reported its Q2 2026 financial results, with revenue increasing to $84.08 million from $69.39 million in the prior year quarter, marking a 21.2% year-over-year growth. The company also narrowed its net loss, reporting a diluted EPS of ($0.12) compared to ($0.27) a year earlier. Key business highlights included strong sales of Jeuveau®, the European launch of Evolysse®, and strategic expansion of distribution rights for its products.
Evolus, Inc. (EOLS) Reports Break-Even Earnings for Q2
Evolus, Inc. (EOLS) reported break-even quarterly earnings per share for Q2 2026, surpassing the Zacks Consensus Estimate of a $0.01 loss and significantly improving from a $0.24 loss a year ago. The company also exceeded revenue expectations, posting $84.08 million against an estimated $82.02 million. Despite outperforming earnings estimates three out of the last four quarters and revenue estimates consistently, Evolus's stock has lost 8% year-to-date, contrasting with the S&P 500's 13% gain.
Evolus Q2 2026 slides: profitability streak continues, guidance raised
Evolus Inc. reported strong Q2 2026 results, with revenue up 21% year-over-year to $84.1 million, marking its third consecutive quarter of positive adjusted EBITDA. The company raised its full-year 2026 revenue guidance to $330-$337 million and reaffirmed its long-term target of $450-$500 million by 2028, driven by its expanding portfolio of aesthetic injectables and a digital-first customer engagement strategy. Despite a wider-than-expected adjusted loss per share, investors reacted positively to the revenue beat and improved outlook, as Evolus transitions from a single-product business to a diversified aesthetics platform.
Evolus (EOLS) Releases Q2 2026 Earnings: Revenue Growth and Narrower Losses
Evolus (EOLS) reported strong Q2 2026 earnings with revenue reaching $84.1 million, a 21.2% increase year-over-year, and slightly exceeding estimates. The company also narrowed its net and operating losses, reporting a net loss of $8.1 million and diluted EPS of -$0.12. Insider trading activity showed four sales and no purchases in the last six months, while hedge funds demonstrated mixed sentiment, with some significantly increasing and others decreasing their positions.
Evolus (EOLS) Releases Q2 2026 Earnings: Revenue Growth and Narrower Losses
Evolus (EOLS) reported strong Q2 2026 earnings, with revenue reaching $84.1 million, a 21.2% increase year-over-year, and slightly exceeding analyst estimates. The company also improved its financial performance by narrowing its operating and net losses. Insider trading activity showed sales by executives, while institutional investors had mixed movements in their holdings.
Evolus (NASDAQ: EOLS) lifts 2026 guidance after Q2 revenue hits $84.1 million
Evolus (NASDAQ: EOLS) reported strong Q2 2026 financial results with net revenue of $84.1 million, a 21% increase year-over-year, and positive adjusted EBITDA of $4.7 million. This marks the third consecutive quarter of positive adjusted EBITDA for the company. Consequently, Evolus has raised its full-year 2026 net revenue guidance to between $330 million and $337 million and its adjusted gross profit margin guidance to 67.0% to 67.5%, while reaffirming its 2028 long-term financial outlook.
Perceptive Advisors LLC Acquires New Stake in Evolus, Inc. $EOLS
Perceptive Advisors LLC has acquired a new stake in Evolus, Inc. (NASDAQ:EOLS), purchasing 1,286,862 shares valued at approximately $5.3 million, giving them a 1.95% ownership. Evolus reported revenue slightly above estimates but an adjusted loss that missed expectations. Despite a consensus "Moderate Buy" rating from analysts with a target price of $16.00, the stock is currently trading at $5.84.
Evolus Deadline Alert
Faruqi & Faruqi, LLP is investigating potential claims against Evolus, Inc. (NASDAQ: EOLS) and reminds investors of the December 15, 2020 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that Evolus made false and misleading statements regarding the origin and manufacturing process of its Jeuveau™ product, which were purportedly misappropriated from Medytox. The firm encourages investors who suffered losses exceeding $100,000 to contact them to discuss their legal options.
Evolus, Inc. (NASDAQ: EOLS) extends Estyme deal to $500M markets
Evolus, Inc. has expanded its licensing agreement with Symatese Aesthetics to include exclusive commercialization rights for the Estyme® injectable hyaluronic acid gels in Canada, Australia, and New Zealand. This expansion, costing Evolus an upfront payment of €920,000 and potential regulatory milestone payments of up to €1.38 million, aims to commercialize the product by 2028. The company targets a combined annual market of approximately $500 million for neurotoxins and dermal fillers in these regions, expecting the deal to enhance international gross margins and leverage its existing commercial infrastructure.
Evolus expands hyaluronic acid gel rights to three markets
Evolus Inc. has expanded its licensing and distribution agreement with Symatese to gain exclusive rights for commercializing Estyme injectable hyaluronic acid gels in Canada, Australia, and New Zealand. This move adds three new markets to Evolus's hyaluronic acid gel portfolio, with commercialization expected by 2028, subject to regulatory approvals. The company anticipates this expansion will strengthen its competitive position and be accretive to its international gross margins.
Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand
Evolus, Inc. has expanded its partnership with Symatese to gain exclusive rights to commercialize the Estyme® collection of injectable hyaluronic acid (HA) gels in Canada, Australia, and New Zealand. This expansion will complement Evolus' existing neurotoxin offerings (Jeuveau® and Nuceiva®) in these markets, creating a consistent multi-product commercial platform globally. The agreement is expected to be accretive to Evolus' international gross margins and leverage its existing commercial infrastructure, with commercialization anticipated in 2028 pending regulatory approvals.
Evolus Number of Employees 2026 | Employee Count & Headcount Data
Evolus, Inc. (EOLS) had approximately 348 employees worldwide as of March 2026, marking a 50.4% growth since 2023 but a 4.0% decline year-over-year in 2026. The company is actively hiring, with 53 job postings in 2026, and its workforce is predominantly located in the United States. The average salary is $137,590, and overall employee sentiment is neutral but declining.
Evolus Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance
This article provides a detailed profile of Evolus, Inc. (EOLS), a performance beauty company specializing in cash-pay aesthetic medical products. It outlines the company's key products, Jeuveau and Evolysse, and includes essential corporate information such as its CEO, IPO date, employee count, and contact details. The article also lists company executives with their shareholdings and provides data on institutional ownership of Evolus Inc.
Evolus Inc (EOLS) Financial Health: Profitability & Balance Sheet Analysis
The financial score for Evolus Inc (EOLS) is 8.00, placing it 82nd out of 155 in the Pharmaceuticals industry, indicating a weak financial status but high operating efficiency. The company reported a 6.74% year-over-year increase in its latest quarterly revenue to $73.14M and a 43.50% increase in net profit. While some financial data for specific metrics like cash equivalents, total assets, and free cash flow were not disclosed, its operational efficiency and growth potential scores are high.
Evolus Shareholder Alert
Faruqi & Faruqi, LLP, a securities law firm, is investigating potential claims against Evolus, Inc. following a federal securities class action lawsuit. The lawsuit alleges that Evolus made false statements regarding the origin of its Jeuveau™ product and misappropriated trade secrets from Medytox. This led to a significant stock drop after the U.S. International Trade Commission recommended banning the import and sale of Jeuveau™.
How Evolus Inc. (EOLS) Affects Rotational Strategy Timing
This article analyzes Evolus Inc. (EOLS) utilizing AI models to provide insights for a rotational strategy. It highlights a near-term strong sentiment challenging persistent mid and long-term weakness and identifies a significant risk-reward setup. The analysis offers three distinct institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for various horizons.
Evolus Inc (EOLS) Institutional Confidence
The article provides an overview of Evolus Inc's institutional confidence, detailing its current score, industry ranking, and institutional shareholding proportion, which has decreased by 14.84% quarter-over-quarter. It lists key institutional shareholders and their recent activity. The institutional shareholding score for EOLS is 7.00, placing it 50th out of 155 in the Pharmaceuticals industry.
Evolus Inc (EOLS) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Evolus Inc (EOLS), detailing its price movement, support and resistance levels, and insights from various technical indicators and moving averages. The stock currently has a price momentum score of 4.73 and is trading between a resistance of $7.16 and support of $5.37. While some indicators suggest a "Sell" or "Neutral" signal, moving averages largely indicate a "Buy" signal.
Evolus Market Sentiment
This article analyzes market sentiment for Evolus (EOLS) through key signals like analyst consensus, short interest, options flow, and insider activity. It highlights that analysts have a "Buy" consensus with an average price target significantly above the current stock price, despite some recent downgrades and maintained ratings. The article also touches on recent insider buying activity and upcoming earnings information for Evolus.
Evolus Inc (EOLS) Cash Flow
This article provides a detailed historical cash flow statement for Evolus Inc (EOLS), covering annual and quarterly data across various financial metrics like operating, investing, and financing cash flows. It includes period-over-period changes and absolute values for numerous line items, allowing for an in-depth analysis of the company's financial liquidity and health. The data spans from FY2016Q3 to FY2026Q1, highlighting trends in net income, capital expenditures, and changes in working capital.
Evolus Inc (EOLS) Income Statement
This article provides the quarterly and annual income statement for Evolus Inc (EOLS), detailing key financial metrics such as total revenue, cost of revenue, operating expenses, operating profit, and net income. It allows users to gain insights into the company's financial performance and operational efficiency over various periods. The page also includes FAQs explaining how to interpret the income statement and defining important financial terms like YOY (year over year) and EPS (earnings per share).
Evolus Inc (EOLS) Balance Sheet
This article provides the quarterly and annual balance sheets for Evolus Inc (EOLS), allowing users to evaluate the company's financial health, fundamentals, and key financial ratios. It details assets, liabilities, and shareholder equity over various fiscal quarters, and includes a FAQ section defining key financial terms and recent figures for EOLS.
Evolus Inc (EOLS) Dividends & Stock Splits: Historical Payouts and Event Timeline
The article provides information regarding Evolus Inc (EOLS) stock, focusing on its dividend history. It states that Evolus Inc has not distributed any dividends over the past five years. The page displays current stock metrics such as its closing price, market capitalization, and P/E TTM.
Evolus Inc (EOLS) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Evolus Inc (EOLS), listing major individual and institutional holders, their proportion of shares, and recent changes in their holdings. It also categorizes shareholders by type (e.g., Hedge Fund, Investment Advisor) and provides data on institutional shareholding trends over several quarters. Lastly, it identifies several ETFs with holdings in Evolus Inc.
Evolus, Inc. Common Stock Revenue Breakdown – NASDAQ:EOLS
Evolus, Inc. (NASDAQ: EOLS) generated $297.18 million USD in revenue last year, primarily from its Medical Aesthetics segment. All of this revenue came from the United States, which contributed $297.18 million USD last year, an increase from $253.16 million USD the previous year. This indicates a strong focus on the medical aesthetics market within the US.
Evolus Inc (EOLS) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Evolus Inc (EOLS) from TradingKey. The company currently has a valuation score of 9.32, which ranks it 30th out of 155 in the Pharmaceuticals industry. While its current P/E ratio is -9.25, the article notes that key P/B, P/S, and P/CF data have not yet been disclosed by the company.
Press Release: Evolus to Report Second Quarter Financial Results on August 5, 2026
Evolus, Inc. announced it will release its second quarter financial results on August 5, 2026. The announcement will be followed by a conference call and webcast for investors and analysts to discuss the results and provide a business update.
Evolus to Report Second Quarter Financial Results on August 5, 2026
Evolus, Inc. (NASDAQ: EOLS) announced it will report its second quarter 2026 financial results on Wednesday, August 5, 2026, after the U.S. financial markets close. The company will host a conference call and live webcast at 4:30 p.m. ET on the same day to discuss the results, followed by a Q&A session. Investors can access the webcast on the Evolus website's Investor Relations page, with a telephonic replay and archived webcast available afterwards.
(EOLS) and the Role of Price-Sensitive Allocations
This article provides an AI-generated analysis of Evolus Inc. (NASDAQ: EOLS) revealing weak sentiment across all time horizons, suggesting a short bias. It outlines three distinct trading strategies (Position Trading, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss levels. The analysis emphasizes a strong risk-reward setup with a target gain of 26.4% versus 0.4% risk.
Evolus, Inc. (EVL) Q3 2025 Earnings Report - Results, Call & Slides
Evolus, Inc. (EVL) reported its Q3 2025 earnings, surpassing analyst expectations with an actual EPS of -€0.12 against a consensus of -€0.14, and actual revenue of €60.28M against an expected €58.90M. The company experienced a 12.90% year-over-year revenue growth. The next earnings report for Evolus is projected for August 5, 2026.
Analysts Conflicted on These Healthcare Names: Irhythm Technologies (IRTC), Penumbra (PEN) and Evolus (EOLS)
This article highlights recent analyst ratings for several healthcare companies. Irhythm Technologies (IRTC) received a "Strong Buy" consensus with a significant upside, while Penumbra (PEN) garnered a "Hold" consensus. Evolus (EOLS) also received a "Strong Buy" consensus rating with a high potential upside.
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus, Inc. announced the grant of 115,000 restricted stock units (RSUs) to 38 newly hired non-executive employees between April and July 2026. These inducement awards were approved by the compensation committee under Evolus' 2023 Inducement Incentive Plan, as material inducements for joining the company, in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest 25% annually, contingent on continuous employment.
Evolus Class Action Reminder
Faruqi & Faruqi, LLP is reminding investors who suffered losses exceeding $100,000 in Evolus (NASDAQ: EOLS) stock or options between February 1, 2019, and July 6, 2020, to contact them. The firm is investigating potential claims that Evolus made misleading statements regarding its Jeuveau™ product and its misappropriation of trade secrets, which led to a significant stock drop after a U.S. International Trade Commission ruling. Investors have until December 15, 2020, to seek the role of lead plaintiff in the federal securities class action.
ETFs Investing in Evolus, Inc. Stocks
This article lists various ETFs that invest in Evolus, Inc. (EVL) stocks, providing details such as market value, weight, issuer, management style, expense ratio, and AUM. The funds primarily focus on small-cap, total market, micro-cap, and healthcare sectors, offering investors diversified exposure to the pharmaceutical company. The data helps investors evaluate different ETF options for potentially lower-risk investments in Evolus.
Evolus Partners With IBSA to Develop, Commercialize Profhilo in US
Evolus has partnered with IBSA to develop and commercialize Profhilo, an injectable aesthetic treatment, in the United States. This collaboration aims to bring a new bio-remodeling product to the US market, expanding Evolus's portfolio beyond neuromodulators and adding an immediate revenue stream. The partnership is expected to strengthen Evolus's position in the aesthetic biologics market.
Evolus, IBSA Partner to Develop and Commercialize Skin Quality Filler in the US
Evolus has entered into an exclusive licensing and distribution agreement with IBSA to develop and commercialize Profhilo, a hyaluronic acid-based injectable for skin quality improvement, in the United States. This partnership expands Evolus's presence in the aesthetic market, targeting a rapidly growing segment. The agreement is structured as a transfer-price model with no upfront payments and is not expected to alter Evolus's previously stated financial outlook for 2026 and 2028.
Evolus signs licensing deal for Profhilo skin injectable in US
Evolus Inc. has signed an exclusive licensing and distribution agreement with IBSA to commercialize Profhilo, a hyaluronic acid skin injectable, in the United States. This agreement allows Evolus to expand its aesthetic product portfolio, complementing its existing neurotoxin and dermal filler offerings. The deal is structured as a transfer-price model with no upfront payments and is not expected to impact Evolus's previously communicated financial outlooks for 2026 and 2028.
Evolus signs licensing deal for Profhilo skin injectable in US By Investing.com
Evolus Inc. has signed an exclusive licensing and distribution agreement with Swiss pharmaceutical company IBSA to bring Profhilo, a hyaluronic acid skin injectable, to the United States. This strategic move expands Evolus's aesthetic product portfolio, which already includes Jeuveau and Evolysse, into the rapidly growing skin quality injectable segment. The agreement is not expected to affect Evolus's near-term financial outlook, and the company notes that Profhilo has seen significant use globally since its 2015 launch.
Evolus Secures Exclusive U.S. Profhilo License From IBSA; No Upfronts, 15-Year Term
Evolus has secured an exclusive 15-year U.S. license, supply, and distribution agreement with IBSA for Profhilo, an injectable hyaluronic acid product for skin quality. Evolus will manage the U.S. development, clinical work, and regulatory approval, with no upfront or milestone payments involved. The agreement includes purchase requirements starting in year four and allows for renewals.
Evolus adds Profhilo, a skin-quality injectable sold in 70+ countries
Evolus, Inc. announced an exclusive licensing and distribution agreement with IBSA to bring Profhilo®, a leading skin-quality injectable, to the United States. This partnership expands Evolus's injectable portfolio into the rapidly growing skin quality segment, complementing its existing neurotoxin and dermal filler offerings. Profhilo® has a strong international track record, with over 4.8 million treatments administered globally since 2015, and is expected to capitalize on the unmet need and growth opportunity in the U.S. aesthetics market.
